This episode delivers a deep, unfiltered breakdown of the latest Retatrutide data—showing weight-loss results that approach and even rival bariatric surgery—while exposing the growing battle over access, pricing, and Lilly’s push to classify the drug as a biologic. It also examines the exploding gray market, new telehealth outcomes, and why the future of obesity medicine will depend on protecting patient access to these life-changing treatments.